Galc Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Symbol | GALC |
| Full Name | Galactocerebrosidase |
| Chromosomal Location | 14q31.3 (Chr14: 87,934,475-88,013,430) |
| NCBI Gene ID | 2581 |
| OMIM | 245000 |
| Ensembl ID | ENSG00000135837 |
| UniProt | P54803 |
GALC encodes galactocerebrosidase, a lysosomal hydrolase that catalyzes the hydrolysis of galactocerebroside, a major lipid component of myelin. This enzyme is essential for normal myelin maintenance and repair.
| Age of Onset | Form | Progression |
|---|---|---|
| 0-6 months | Infantile | Rapid, fatal by age 2 |
| 6 months - 5 years | Late infantile | Progressive |
| 5-10 years | Juvenile | Slower progression |
| >10 years | Adult | Variable, often milder |
The study of Galc Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
1.雪花秀 (Lancet Neurol. 2019). For Krabbe disease gene therapy.
2. Luziga C, et al. GALC mutations and disease mechanisms. Exp Neurol. 2020;328:113288.
3. Sakai N, et al. Molecular analysis of the GALC gene in Krabbe disease. J Hum Genet. 2019;64(2):139-148.
VMAT2 is a critical therapeutic target in Parkinson's disease. The vesicular monoamine transporter packages dopamine into synaptic vesicles, protecting it from oxidative degradation in the cytoplasm. Reduced VMAT2 expression may contribute to increased cytosolic dopamine oxidation and oxidative stress in dopaminergic neurons. Additionally, VMAT2 imaging can serve as a biomarker for dopaminergic neuron integrity.
PET imaging with VMAT2 ligands such as [^11C]tetrabenazine and [^18F]fluoroethyl-L-tyrosine (FET) can visualize VMAT2 density in the brain. These imaging agents are used to assess dopaminergic neuron loss in Parkinson's disease and related disorders. Reduced VMAT2 binding correlates with disease severity and progression.
Tetrabenazine is a VMAT2 inhibitor approved for the treatment of chorea in Huntington's disease. By depleting vesicular dopamine, tetrabenazine reduces hyperkinetic movements. Deutetrabenazine, a deuterium analog, offers improved pharmacokinetics and reduced side effects compared to tetrabenazine.
Reserpine is an older VMAT2 inhibitor that depletes monoamines including dopamine, norepinephrine, and serotonin. While effective for movement disorders, its use has declined due to side effects including depression and hypotension. Research into VMAT2 modulators continues for potential neuroprotective strategies.
VMAT2 deficiency may lead to impaired autophagy and increased susceptibility to neurodegeneration. Studies in VMAT2 knockout mice show accumulation of autophagic vacuoles and progressive neurodegeneration. This suggests that VMAT2 function is important for cellular clearance mechanisms that protect against protein aggregation.
Dopamine packaged in vesicles by VMAT2 is protected from mitochondrial oxidation. When VMAT2 function is impaired, increased cytosolic dopamine leads to enhanced mitochondrial reactive oxygen species production. This mechanism may contribute to the selective vulnerability of dopaminergic neurons in Parkinson's disease.
VMAT2 expression is regulated by multiple transcription factors including Nurr1, Pitx3, and REST. These factors are important for dopaminergic neuron development and maintenance. Dysregulation of VMAT2 transcription may contribute to dopaminergic dysfunction in disease states.
DNA methylation and histone modifications can affect VMAT2 expression. Studies have found altered VMAT2 promoter methylation in Parkinson's disease brains, suggesting epigenetic mechanisms may contribute to reduced VMAT2 in disease.